Related Experiment Videos
Development of molecular agents for IGF receptor targeting.
1Cancer Research UK Laboratories, Weatherall Institute of Molecular Medicine, Oxford OX3 9DS UK.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|January 8, 2004
Summary
Targeting the type 1 insulin-like growth factor receptor (IGF1R) with molecular agents shows promise for cancer treatment. IGF1R gene silencing inhibits tumor growth, enhances drug sensitivity, and may stimulate anti-tumor immunity.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed in many tumors, driving cancer cell proliferation, motility, and survival.
- Designing specific IGF1R kinase inhibitors is challenging due to structural homology with the insulin receptor.
Purpose of the Study:
- To review the development of molecular agents targeting IGF1R for cancer therapy.
- To discuss factors influencing the clinical efficacy and toxicity of IGF1R inhibitors.
Main Methods:
- Exploration of sequence-specific molecular agents like antisense, triplex, ribozymes, and small interfering RNAs (siRNAs) for IGF1R gene silencing.
- Review of studies demonstrating IGF1R downregulation effects on tumor growth, metastasis, drug sensitivity, and DNA repair pathways.
Main Results:
- Small interfering RNAs effectively induce sequence-specific IGF1R gene silencing in mammalian cells.
- IGF1R downregulation inhibits tumor growth and metastasis, enhances sensitivity to cytotoxic agents and irradiation, and impairs DNA damage response pathways.
- IGF1R inhibition can also trigger an anti-tumor immune response.
Conclusions:
- Novel molecular agents targeting IGF1R are nearing clinical availability.
- Clinical success depends on tumor dependence on IGF signaling, and the efficacy and safety profiles of IGF1R inhibitors.